Telemedicine has skyrocketed during the COVID-19 pandemic, but what actions are needed for more patients to have equitable, fair access to genetics services via telegenetics?
Telemedicine has skyrocketed during the COVID-19 pandemic, but what actions are needed for more patients to have equitable, fair access to genetics services via telegenetics?
To address this urgent problem, the Advocacy and Government Affairs Committee of the American College of Medical Genetics and Genomics (ACMG) just released a new Points to Consider statement that will assist policymakers tasked with improving appropriate, broad access to genetics services via telehealth: "Considerations for Policymakers to Improve Healthcare through Telegenetics: A Points to Consider Statement of the American College of Medical Genetics and Genomics."
"We have seen a dramatic increase in telemedicine use during the COVID-19 pandemic, but research suggests access is not equitable across different population groups," said lead author Heather E. Williams, PhD, MS, in a release. "Policy efforts to ensure equitable access to genetics services via telehealth are necessary. We can continue to address disparities by eliminating barriers to accessing the medical genetics workforce."
The statement, the first published by ACMG's Advocacy and Government Affairs (AGA) Committee, is intended to be used by policymakers to consider as they pursue legislative, regulatory, or other policies related to telegenetics or reducing disparities in access to genetic services. It describes telegenetics services, the need for these services, existing barriers to technology access, actions needed to ensure equitable access and the current state of reimbursement for these services.
A few of the specific points to consider include:
The statement concludes that while the COVID-19 pandemic expedited the expanded integration of telemedicine into genetic services, only a concerted effort will ensure that all Americans can benefit from these services. The points discussed in this statement should be viewed as considerations for federal, state and institutional policymakers as well as payers that are tasked with ensuring equitable access to telemedicine, including telegenetics. Improved telehealth policies are necessary to enhance patient care and reduce disparities in accessing genetics healthcare to patients throughout the United States.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More